What is the share price of Eris Lifesciences Ltd (ERIS) today?
The share price of ERIS as on 21st March 2025 is ₹1390.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Eris Lifesciences Ltd (ERIS) share?
The past returns of Eris Lifesciences Ltd (ERIS) share are- Past 1 week: 9.00%
- Past 1 month: 7.14%
- Past 3 months: 0.77%
- Past 6 months: 5.01%
- Past 1 year: 64.99%
- Past 3 years: 92.58%
- Past 5 years: 284.01%
What are the peers or stocks similar to Eris Lifesciences Ltd (ERIS)?
The peers or stocks similar to Eris Lifesciences Ltd (ERIS) include:What is the market cap of Eris Lifesciences Ltd (ERIS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Eris Lifesciences Ltd (ERIS) is ₹18938.85 Cr as of 21st March 2025.What is the 52 week high and low of Eris Lifesciences Ltd (ERIS) share?
The 52-week high of Eris Lifesciences Ltd (ERIS) is ₹1593.90 and the 52-week low is ₹815.85.What is the PE and PB ratio of Eris Lifesciences Ltd (ERIS) stock?
The P/E (price-to-earnings) ratio of Eris Lifesciences Ltd (ERIS) is 48.32. The P/B (price-to-book) ratio is 5.88.Which sector does Eris Lifesciences Ltd (ERIS) belong to?
Eris Lifesciences Ltd (ERIS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Eris Lifesciences Ltd (ERIS) shares?
You can directly buy Eris Lifesciences Ltd (ERIS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Eris Lifesciences Ltd
ERIS Share Price
1,390.901.75% (+23.95)
ERIS Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ERIS Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is underpriced but is in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ERIS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 57.50 | 5.88 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.00 | 6.39 | 0.53% |
ERIS Analyst Ratings & Forecast
Detailed Forecast 89%
Analysts have suggested that investors can buy this stock
from 9 analysts
Price Upside
Earnings Growth
Rev. Growth
ERIS Company Profile
Eris Lifesciences Limited is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian Pharmaceutical Market
Investor Presentation
View olderERIS Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
44.71
1Y Return
14.01%
Buy Reco %
88.24
CIPLA
PE Ratio
29.86
1Y Return
5.19%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
65.86
1Y Return
26.18%
Buy Reco %
68.00
DRREDDY
PE Ratio
17.93
1Y Return
2.08%
Buy Reco %
45.16
MANKIND
PE Ratio
52.09
1Y Return
13.24%
Buy Reco %
80.00
ERIS Forecasts
Price
Revenue
Earnings
ERIS Share Price Forecast
2024
Current
₹1,390.90
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹1,390.90
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ERIS Company Revenue Forecast
2024
Current
₹2.08
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2024
Current
₹2.08
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ERIS Stock EPS (Earnings Per Share) Forecast
2024
Current
₹28.82
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹28.82
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹
ERIS
Income
Balance Sheet
Cash Flow
Annual Normal View
ERIS Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 600.39 | 774.61 | 882.01 | 1,013.85 | 1,089.46 | 1,220.57 | 1,373.13 | 1,743.83 | 2,080.10 | 2,764.83 | ||||||||||
Raw Materials | 89.94 | 107.73 | 136.92 | 167.12 | 150.12 | 276.44 | 259.29 | 348.53 | 379.32 | 1,826.03 | ||||||||||
| Power & Fuel Cost | 3.59 | 3.02 | 3.17 | 3.45 | 4.62 | 3.95 | 4.16 | 5.70 | 12.04 | |||||||||||
| Employee Cost | 124.67 | 131.22 | 157.32 | 190.66 | 205.69 | 229.30 | 250.18 | 346.16 | 403.82 | |||||||||||
| Selling & Administrative Expenses | 189.79 | 204.42 | 224.28 | 279.66 | 238.82 | 210.94 | 256.10 | 375.66 | 426.75 | |||||||||||
| Operating & Other expenses | 17.33 | 33.97 | 11.81 | -3.80 | 106.30 | 60.49 | 92.28 | 119.88 | 159.52 | |||||||||||
EBITDA | 175.07 | 294.25 | 348.51 | 376.76 | 383.91 | 439.45 | 511.12 | 547.90 | 698.65 | 938.80 | ||||||||||
| Depreciation/Amortization | 20.36 | 22.76 | 25.64 | 36.35 | 50.26 | 42.99 | 64.71 | 117.09 | 182.61 | 291.52 | ||||||||||
| PBIT | 154.71 | 271.49 | 322.87 | 340.41 | 333.65 | 396.46 | 446.41 | 430.81 | 516.04 | 647.28 | ||||||||||
| Interest & Other Items | 0.28 | 1.10 | 10.65 | 23.06 | 2.30 | 1.98 | 4.22 | 26.17 | 84.80 | 210.04 | ||||||||||
| PBT | 154.43 | 270.39 | 312.22 | 317.35 | 331.35 | 394.48 | 442.19 | 404.64 | 431.24 | 437.24 | ||||||||||
| Taxes & Other Items | 20.88 | 23.60 | 18.12 | 26.56 | 34.86 | 39.36 | 36.08 | 22.48 | 39.26 | 107.88 | ||||||||||
| Net Income | 133.55 | 246.79 | 294.10 | 290.79 | 296.49 | 355.12 | 406.11 | 382.16 | 391.98 | 329.36 | ||||||||||
| EPS | 9.71 | 17.95 | 21.39 | 21.15 | 21.70 | 26.15 | 29.89 | 28.11 | 28.82 | 24.21 | ||||||||||
| DPS | 6.04 | 0.00 | 0.00 | 0.00 | 2.87 | 5.50 | 6.01 | 7.35 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.62 | 0.00 | 0.00 | 0.00 | 0.13 | 0.21 | 0.20 | 0.26 | 0.00 | 0.00 |
ERIS Company Updates
FY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2025
Investor Presentation
Feb 4PDF
Oct 25PDF
ERIS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Eris Lifesciences Ltd | 48.32 | 5.88 | — |
| Sun Pharmaceutical Industries Ltd | 44.71 | 6.38 | 0.76% |
| Cipla Ltd | 29.86 | 4.59 | 0.85% |
| Torrent Pharmaceuticals Ltd | 65.86 | 15.91 | 0.87% |
ERIS Stock Price Comparison
Compare ERIS with any stock or ETFCompare ERIS with any stock or ETF
ERIS
ERIS Shareholdings
ERIS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ERIS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ERIS Shareholding Pattern
ERIS Shareholding History
Foreign Institutions
Mutual Funds Invested in ERIS
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Eris Lifesciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.7295% | Percentage of the fund’s portfolio invested in the stock 2.51% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/90 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.5361% | Percentage of the fund’s portfolio invested in the stock 1.31% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 70/132 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1659% | Percentage of the fund’s portfolio invested in the stock 1.96% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 8/100 (-1) |
Compare 3-month MF holding change on Screener
smallcases containing ERIS stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Eris Lifesciences Ltd
ERIS Events
ERIS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ERIS Upcoming Dividends
No upcoming dividends are available
ERIS Past Dividends
Cash Dividend
Ex DateEx DateFeb 13, 2025
Interim
Interim | Div/Share: ₹7.35
Dividend/Share
₹7.35
Ex DateEx Date
Feb 13, 2025
Cash Dividend
Ex DateEx DateAug 11, 2022
Interim
Interim | Div/Share: ₹7.35
Dividend/Share
₹7.35
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Interim
Interim | Div/Share: ₹6.01
Dividend/Share
₹6.01
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateAug 13, 2020
Interim
Interim | Div/Share: ₹5.50
Dividend/Share
₹5.50
Ex DateEx Date
Aug 13, 2020
Cash Dividend
Ex DateEx DateMar 19, 2020
Interim
Interim | Div/Share: ₹2.87
Dividend/Share
₹2.87
Ex DateEx Date
Mar 19, 2020
ERIS Stock News & Opinions
Articles & Videos
Corporate
Eris Lifesciences allots 33,287 equity shares under ESOP
Eris Lifesciences has allotted 33,287 equity shares under ESOP on 06 March 2025. The paid-up share capital of the Company accordingly stands increased from Rs. 13,61,29,282/- (13,61,29,282 equity shares of Re. 1/- each) to Rs. 13,61,62,569/- (13,61,62,569 equity shares of Re. 1/- each). Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Eris Lifesciences avails credit facility of Rs 1,000 cr
Eris Lifesciences has availed credit facilities amounting to Rs 1000 crore from Kotak Mahindra Bank (Bank). The aggregate debt level of the company would remain unchanged.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Board of ERIS Lifesciences recommends Interim Dividend
ERIS Lifesciences announced that the Board of Directors of the Company at its meeting held on 06 February 2025, has recommended a Interim dividend of Rs.7.35 per share (i.e.735%), subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
ERIS Lifesciences schedules board meeting
ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 7 February 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
ERIS Lifesciences consolidated net profit declines 18.60% in the December 2024 quarter
Net profit of ERIS Lifesciences declined 18.60% to Rs 83.63 crore in the quarter ended December 2024 as against Rs 102.74 crore during the previous quarter ended December 2023. Sales rose 49.36% to Rs 722.12 crore in the quarter ended December 2024 as against Rs 483.48 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales722.12483.48 49 OPM %34.6636.30 - PBDT197.36161.59 22 PBT116.16115.87 0 NP83.63102.74 -19 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
ERIS Lifesciences to hold board meeting
ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 4 February 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Eris Lifesciences approves acquisition of 30% stake in Levim Lifetech
The Board of Eris Lifesciences at its meeting held on 25 October 2024 has approved the execution of Binding Term Sheet with Levim Lifetech and its shareholders for the purpose of acquiring 30% stake in Levim Lifetech for an investment of Rs 54 crore at a pre-money equity valuation of Rs 126 crore. The acquisition is aimed at expansion of the company's biotechnology footprint across a wide range of products and technologies. Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
ERIS Lifesciences consolidated net profit declines 25.80% in the September 2024 quarter
Net profit of ERIS Lifesciences declined 25.80% to Rs 91.59 crore in the quarter ended September 2024 as against Rs 123.43 crore during the previous quarter ended September 2023. Sales rose 47.64% to Rs 738.95 crore in the quarter ended September 2024 as against Rs 500.52 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales738.95500.52 48 OPM %35.8036.19 - PBDT209.59168.33 25 PBT129.11126.24 2 NP91.59123.43 -26 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
ERIS Lifesciences announces board meeting date
ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
ERIS Lifesciences to convene AGM
ERIS Lifesciences announced that the 18th Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 15.46%, vs industry avg of 9.04%
Over the last 5 years, market share increased from 0.46% to 0.55%
Over the last 5 years, net income has grown at a yearly rate of 6.15%, vs industry avg of 15.27%